Wistar scientists identify genes critical to protecting ovarian cancer from the immune system

Researchers at The Wistar Institute and Temple University have identified a metabolic target that can help overcome chemotherapy resistance in ovarian cancer. Elevated alpha-ketoglutarate activates an enzyme called TMLHE, which drives carnitine production and loosens the DNA-histone complex, allowing cells to access and fix damaged DNA.

Researchers at The Wistar Institute have engineered novel monoclonal antibodies that engage Natural Killer cells through Siglec-7, a conserved glyco-immune marker, to fight against cancer. These new approaches demonstrate preclinical feasibility and potential for treating treatment-resistant ovarian cancers.

Researchers at The Wistar Institute have discovered a new combination therapy approach that shrinks tumors and improves survival rates in metastatic ovarian cancer. By activating myeloid cells, the treatment overcomes immunosuppression around tumors and makes them more receptive to chemotherapy.

Researchers identify CNTD1 mutations as a cause of diminished ovarian reserve, characterized by reduced ovarian follicles and compromised fertility. The study establishes CNTD1's essential role in maintaining ovarian function and preserving the follicular reserve required for female fertility.

Glioblastoma suppresses immune system by inducing pro-tumor macrophages via glucose-based epigenetic modification, allowing tumor growth. Targeting PERK enzyme may be a viable strategy to fight deadly brain cancer.

Scientists at The Wistar Institute have designed a two-vaccine approach targeting T cell receptors and cancer-specific mutations, significantly improving tumor control and survival in preclinical models. The combination therapy, developed in collaboration with Geneos Therapeutics, offers a promising new tool for treating T cell lymphom...